A Phase I, Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 in Refractory Solid Tumor Patients.

Trial Profile

A Phase I, Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 in Refractory Solid Tumor Patients.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2014

At a glance

  • Drugs L-DOS 47 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Apr 2014 Status changed from not yet recruiting to discontinued.
    • 14 Jun 2012 Helix BioPharma has decided not to start this trial until results from its Polish phase I/II trial have been reported according to a Helix BioPharma media release.
    • 05 Mar 2012 Status changed from recruiting to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top